A Phase I, Double-blind, Randomized, Placebo-controlled, Single-dose, Dose-escalation Study of KRN23 in X-linked Hypophosphatemia
Phase of Trial: Phase I
Latest Information Update: 01 Apr 2014
Price : $35 *
At a glance
- Drugs Burosumab (Primary) ; Burosumab (Primary)
- Indications Hyperphosphataemia
- Focus Adverse reactions
- Sponsors Kyowa Hakko Kirin
- 11 Oct 2013 New trial record
- 08 Oct 2013 Results presented at the 35th Annual Meeting of the American Society for Bone and Mineral Research.
- 07 Oct 2013 Results published in a Kyowa Hakko Kirin media release and presented at the American Society of Bone Mineralization Research (ASBMR) 2013 Annual Meeting.